Your browser doesn't support javascript.
loading
Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9].
Li, Jiarui; Cheng, Yuejuan; Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Chi, Yihebali; Yu, Xianjun; Li, Enxiao; Xu, Nong; Liu, Tianshu; Lou, Wenhui; Bai, Yuxian; Yuan, Xianglin; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Guan, Sha; Fan, Songhua; Su, Weiguo.
Afiliação
  • Li J; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Cheng Y; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Bai C; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: baichunmei1964@163.com.
  • Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: jmxu2003@yahoo.com.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: linshenpku@163.com.
  • Li J; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhou Z; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Li Z; Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Chi Y; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yu X; Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Li E; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
  • Liu T; Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.
  • Lou W; Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.
  • Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang X; Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan.
  • Yuan Y; Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Chen J; Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.
  • Guan S; Department of Clinical and Regulatory Affairs, HUTCHMED, Shanghai, China.
  • Fan S; Department of Clinical and Regulatory Affairs, HUTCHMED, Shanghai, China.
  • Su W; Department of Clinical and Regulatory Affairs, HUTCHMED, Shanghai, China.
Eur J Cancer ; 178: 247-248, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36402625

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article